Valneva appoints Scientific Director
Specifically, she will focus on accelerating Valneva's preclinical and translational R&D activities, with the aim of supporting its strategic ambition to deliver innovative vaccine solutions.
Dr Schuitemaker has over twenty years' experience in vaccine discovery and development, including nearly 14 years as global head of viral vaccine discovery and translational medicine at Johnson & Johnson.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction